Medicare Expands Price Negotiations to Include Ozempic, Wegovy, and 13 Other Key Medications
Medicare Expands Drug Price Negotiations to Include Ozempic, Wegovy, and Other Popular Medications
The Biden administration announced Friday that Medicare will begin negotiating prices for 15 additional prescription drugs, including popular weight loss and diabetes medications like Ozempic and Wegovy. The move, part of a broader effort to lower drug costs for older Americans, brings the total number of medications subject to price negotiations to 25.
The newly selected drugs, which also include treatments for asthma, cancer, and psoriatic arthritis, account for a significant portion of Medicare’s prescription spending. U.S. Health and Human Services Secretary Xavier Becerra emphasized the impact of high drug costs on patients, noting that some individuals skip doses to stretch their prescriptions.
“For some people, this is a big deal,” Becerra said during a call with reporters. “Some folks have to skip a dose in their prescription so they can make it last longer.”
The negotiations, authorized under a law passed by Democrats and signed by President Joe Biden, mark a historic shift in Medicare’s ability to directly negotiate drug prices. Previously, the program was legally barred from such negotiations. The law has faced opposition from pharmaceutical companies, which have filed lawsuits to block the process.
The Pharmaceutical Research and Manufacturers of America (PhRMA), a leading industry lobby, criticized the move, calling on the incoming Trump administration and Congress to address what it described as the “true challenges facing seniors and Medicare.”
Despite the pushback, the negotiations are expected to yield significant savings. The first round of deals, announced late last year, reduced prices for 10 drugs by hundreds or even thousands of dollars per 30-day supply. Those savings are projected to generate $6 billion for taxpayers and $1.5 billion for Medicare enrollees.
The latest round of negotiations includes medications like Trelegy Ellipta for asthma, Otezla for psoriatic arthritis, and several cancer treatments. However, Medicare enrollees will still face restrictions on accessing Ozempic and Wegovy for weight loss. Under current law, the program only covers these drugs for diabetes or blood sugar management. A proposed rule by the Biden administration could expand coverage to include weight loss, but the decision will ultimately fall to the incoming Trump administration.
The negotiated prices for the first 10 drugs will take effect in 2026, while the newly announced medications will see price reductions starting in 2027. In the meantime, Medicare enrollees will benefit from a new rule capping annual out-of-pocket prescription costs at $2,000, set to take effect this year.
The 15 drugs added to the negotiation list include Ozempic, Rybelsus, Wegovy, Trelegy Ellipta, Xtandi, Pomalyst, Ibrance, Ofev, Linzess, Calquence, Austedo, Breo Ellipta, Tradjenta, Xifaxan, Vraylar, Janumet, and Otezla.
As the negotiation process continues, more drugs are expected to be added in the coming years, potentially reshaping how Medicare manages prescription costs for millions of Americans.
The Biden administration’s decision to expand Medicare’s drug price negotiations to include widely used medications like Ozempic, Wegovy, and other critical treatments marks a notable step forward in addressing the soaring costs of prescription drugs. By targeting 15 additional medications, bringing the total to 25, this initiative underscores a commitment to making healthcare more affordable and accessible for older Americans. The inclusion of drugs for conditions such as diabetes, obesity, asthma, and cancer reflects a recognition of the financial burden these treatments place on patients and the healthcare system as a whole.
As U.S. Health and Human Services Secretary Xavier Becerra highlighted, the high cost of medications has forced many to ration or skip doses, jeopardizing their health and well-being. This expansion of price negotiations not only aims to alleviate financial strain but also ensures that patients can access the treatments they need without compromise. While the full impact of these negotiations will unfold over time, this move signals a pivotal shift toward a more equitable and sustainable healthcare system. For millions of americans, it represents hope for a future where life-saving medications are within reach, not just a privilege for the few.
the Biden managementS decision to expand Medicare’s drug price negotiations to include widely used medications like Ozempic, Wegovy, and other critical treatments represents a pivotal step toward addressing the soaring costs of prescription drugs in the United States. By targeting 15 additional medications, Medicare is now negotiating prices for a total of 25 drugs, many of which are essential for managing chronic conditions such as diabetes, asthma, and cancer. this initiative not only underscores the administration’s commitment to making healthcare more affordable but also highlights the tangible impact of policy changes on the lives of millions of older Americans who have long struggled with the financial burden of high drug costs.
While the move has faced staunch opposition from pharmaceutical companies and legal challenges, the potential benefits are undeniable. The projected savings from the first round of negotiations—billions of dollars for taxpayers and enrollees alike—demonstrate the effectiveness of this approach. As Medicare continues to expand its efforts, the hope is that more patients will no longer have to choose between their health and their financial stability.
Ultimately, this policy shift marks a historic milestone in the fight for affordable healthcare. By prioritizing the needs of patients over profit margins, the biden administration is paving the way for a more equitable and enduring healthcare system. As these negotiations progress, thay serve as a reminder of the power of policy to create meaningful change and improve the quality of life for countless Americans.